These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 21402055)

  • 1. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
    Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
    Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
    Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.
    Oliveras-Ferraros C; Fernández-Arroyo S; Vazquez-Martin A; Lozano-Sánchez J; Cufí S; Joven J; Micol V; Fernández-Gutiérrez A; Segura-Carretero A; Menendez JA
    Int J Oncol; 2011 Jun; 38(6):1533-47. PubMed ID: 21455577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
    Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
    Suzuki Y; Saito Y; Terao M; Terada M; Morioka T; Tsuda B; Okamura T; Niikura N; Tokuda Y
    Tokai J Exp Clin Med; 2010 Dec; 35(4):148-51. PubMed ID: 21319046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.